| 1 | Clinical analysis of myocardial injury in highlanders with pulmonary hypertension |
|----|---|
| 2 | |
| 3 | Maolin Zhao ^{1#} , Qianjin Wu ^{2#} , Wangsheng Duanmu ³ , Junxian Shen ³ , Weixin Yuan ³ , Yingbin |
| 4 | Sun ⁴ , Xu Zhang ⁴ , Jinbao Zhang ¹ , Siyi He ^{1*} |
| 5 | |
| 6 | 1 Department of cardiovascular surgery, Affiliated Hospital of Southwest Jiaotong University, |
| 7 | The General Hospital of Western Theater Command, Chengdu, China. |
| 8 | 2 Department of health service, Tibetan Military General Hospital, Lhasa, China. |
| 9 | 3 Department of neurology, Tibetan Military General Hospital, Lhasa, China. |
| 10 | 4 Department of cardiology, Tibetan Military General Hospital, Lhasa, China. |
| 11 | |
| 12 | |
| 13 | # These authors contributed equally to this article. |
| 14 | |
| 15 | * Correspondence to Siyi He. Address: General Hospital of Western Theater Command, |
| 16 | Rongdu Avenue No.270, Jinniu District, Chengdu City, Sichuan Province, China, 610083. |
| 17 | Phone: +86-13558837339. Email: hesiyi@vip.163.com |
| 18 | |
| 19 | |

1 Abstract

| 2 | Background: High altitude environment can give rise to Myocardial injury (MI) mainly |
|----|--|
| 3 | because of hypoxia, where MI with pulmonary hypertension (PH) is one of the severe |
| 4 | pathologies. In the present study, we intend to explore clinical characteristics of MI in patients |
| 5 | with PH at high altitude and diagnostic value of various myocardial markers. |
| 6 | Methods: Consecutive patients at the altitude of 3650m were selected into this retrospective |
| 7 | study. Clinical and biochemical data were collected. According to the results of Cardiac |
| 8 | troponin I (cTnI), patients were divided into MI group and non-MI group. |
| 9 | Results: A total of 231 patients were enrolled in this study. MI occurred in 29 patients |
| 10 | (12.6%). We found that body mass index (BMI, $P=0.045$), left ventricular end-diastolic |
| 11 | dimension (LVEDD, P=0.005), and serum level of creatine kinase-MB (CK-MB, P=0.001) in |
| 12 | MI group were significantly higher than that in non-MI group. Spearman correlation analysis |
| 13 | revealed that cTnI have a significant positive correlation with CK-MB (P=0.000) and LDH (P |
| 14 | <0.001) instead of aspartate aminotransferase (AST). A receiver operating characteristic |
| 15 | (ROC) curve was drawn to demonstrate that CK-MB could significantly predict the |
| 16 | occurrence of MI with an area under the curve (AUC) of 0.749 (P=0.000), and the level of |
| 17 | 3.035 (sensitivity = 59.3%, specificity = 90.5%) was optimal cutoff value. |
| 18 | Conclusion: The incidence of MI with PH is high in highlander. As a convenient and efficient |
| 19 | marker, CK-MB is closely associated with cTnI and have a predict role in the occurrence of |
| 20 | MI with PH under expose to high altitude hypoxia. |
| 21 | |

22 Keywords: creatine kinase-MB, myocardial injury, high altitude, myocardial enzymes,

- 1 pulmonary hypertension
- 2
- 3
- 4

1 1. Introduction

| 2 | The number of people visiting and living in high altitude has increased in recent years. It |
|----|--|
| 3 | is estimated that 81.6 million people live at $> 2,500$ m and 14.4 million people live at $\ge 3,500$ |
| 4 | m ^[1] . High altitude is characterized by hypobaric and hypoxia. The heart is highly sensitive to |
| 5 | hypoxia and prolonged exposure to altitude-associated chronic hypoxia may cause myocardial |
| 6 | injury (MI), which is characterized by varying degrees of elevation of serum myocardial |
| 7 | enzymes. High altitude environment tends to cause increased pulmonary circulation |
| 8 | resistance, thus formating pulmonary hypertension (PH), which is one of the most common |
| 9 | abnormal cardiovascular complications ^[3] . Hypoxia-induced PH is a major health problem at |
| 10 | high-altitude regions of the world. Previous study on Kyrgyz highlanders have reported 14- |
| 11 | 20% of the population with PH ^[4] . Furian et al. ^[5] suggested that highlanders with PH at high |
| 12 | altitude may be at increased risk of cardiovascular mortality and morbidity. Therefore, more |
| 13 | attention should be paid on the MI with PH at high altitude. |
| 14 | MI is a severe complication in population exposed to high altitude and may leads to |

malignant arrhythmias, heart failure, and even sudden death^[6]. Our previous study found that 15 16 the incidence of MI was as high as 33.2% in population transferring from high altitude^[7]. Hypoxic and hypobaric environment will cause the damage of the cardiac cells, leading to the 17 elevation of serum myocardial enzymes to varying degrees^[8]. Cardiac troponin I (cTnI) and T 18 19 (cTnT) are expressed almost exclusively in the heart, which are preferred biomarkers of MI with high specificity and sensitivity^[9]. Thus, they have been regarded as the gold-standard 20 marker for MI^[10]. However, it is difficult to detect cTnI for the reason that the work of 21 22 instruments is limited at high altitude. Thus, it is important to investigating the other classical

| 1 | MI markers to replace troponin for the prevention and diagnosis of MI at high altitude, such |
|---|---|
| 2 | as creatine kinase (CK), lactic dehydrogenase (LDH), and aspartate aminotransferase |
| 3 | (AST) ^[11] . Several studies have used these myocardial enzymes as indicators for the evaluation |
| 4 | of MI at high altitude. He et al. ^[12] found that CK, CK-MB, and LDH levels altered in high- |
| 5 | altitude de-acclimatization syndrome after exposure to high altitudes. Zhou et al. ^[13] |
| 6 | suggedted that the cardiac function index was negatively correlated with the levels of creatine |
| 7 | kinase-MB (CK-MB) and LDH. |

8 In this study, population exposed to high altitude with PH were included, and 9 comparisons between MI and non-MI were analyzed. We intended to explore the diagnostic 10 value of various myocardial markers for MI in patients with PH at high altitude, thereby 11 providing theoretical basis for early clinical prevention and treatment.

12

13 2. Materials and Methods

14 2.1 Study settings

15 Consecutive patients admitted to the department of cardiovascular medicine in a general 16 tertiary hospital at the altitude of 3650m were included. Inclusion criteria: (1) Based on ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension^[14], all 17 18 included patients were diagnosed with PH by using echocardiography with the criteria of 19 tricuspid valve regurgitation (TVR) peak velocity > 280 cm/s; (2) adult patients aged >18 20 years old; (3) living continuously at high altitude (>3000m) more than one year. Exclusion 21 criteria: (1) all kinds of cardiomyopathy, including ischemic, dilated, hypertrophic, and so on; 22 (2) pulmonary embolism; (3) myocarditis; (4) congenital heart disease. According to the

fourth universal definition of myocardial infarction^[15], patients were diagnosed with MI once
the serum level of cTnI was greater than 0.1ng/ml, who were classified into MI group while
the others were classified into non-MI group.

4 2.2 Data collection

5 Basic information of patients was collected through electronic medical record, including 6 age, gender, body mass index (BMI), living altitude, aborigines, and smoke. 7 Echocardiography and electrocardiogram were performed after admission, and then we could 8 get the indexes including TVR velocity, left ventricular end-diastolic dimension (LVEDD) 9 and heart rate (HR). Early morning fasting blood was drawn from all patients after admission 10 for examination to acquire the data about red blood cell count (RBC), hemoglobin (Hb), 11 platelet count, red blood cell distribution width (RDW), platelet distribution width (PDW), 12 alanine transaminase (ALT), AST, total bilirubin, direct bilirubin, albumin, globulin, urea 13 nitrogen, creatinine, uric acid, total cholesterol, triglyceride, high density lipoprotein 14 cholesterin (HDL-C), low density lipoprotein cholesterin (LDL-C), apolipoprotein A1 15 (ApoA1), apolipoprotein B (ApoB), LDH, CK-MB, prothrombin time (PT), activated partial 16 thromboplastin time (APTT) and D-dimer (D-D).

17 2.3 Statistical analysis

The software SPSS version 25.0 was used to perform statistical analysis, and difference was considered to be significant once P value was lower than 0.05. Normal distribution was examined according to Kolmogorov-Smirnov test. Normally distributed measurement data were expressed as mean value \pm standard deviation, and comparisons between groups were analyzed by using t test. Abnormally distributed measurement data were expressed as median

1 value (Q1-Q3), and comparisons between groups were analyzed by using Mann-Whitney U 2 test. Comparisons of enumeration data between groups were analyzed by using chi-square 3 test. Spearman analysis was used to evaluate the correlation between two indexes. Diagnostic 4 accuracy was evaluated by receiver operating characteristic (ROC) curve as assessed by area 5 under the ROC curve (AUC). The optimal cut-off values were determined by using the 6 Youden index. 7 2.4 Patient and public involvement 8 This study was retrospective, and all patients were not initiative to be enrolled in the 9 present research. Medical data were collected through electronic medical record system. No 10 personal information about the patients were included in this study. 11 12 3. Results 13 3.1 Clinical features of MI with PH patients at high altitude 14 A total of 231 patients at high altitude with PH were included in the present study, of 15 which 29 patients were diagnosed with MI, accounting for 12.6%. As Table 1 showed, 16 patients in MI group had higher BMI than those in non-MI group [(26.1±4.0) kg/m2 vs. 17

17 (24.4 ± 4.2) kg/m2, P=0.045]. LVEDD was significantly increased in MI group compared with

18 non-MI group [44(41.5-52.5) mm vs. 42(40-45) mm, P=0.005]. Once MI occurred, the serum

19 level of CK-MB could also significantly upregulate [3.47(2.1-7.6) U/L vs. 1.37(1.1-2.4) U/L,

20 P=0.001].

21 **3.2** Correlation between cTnI and other myocardial enzymes

22 As Table 2 showed, the level of cTnI was positively correlated with the level of CK-MB

1 (r=0.571, P=0.000) and LDH (r=0.212, P=0.001). There was no significant correlation

2 between the level of AST and cTnI.

3 3.3 Diagnostic value of myocardial markers

ROC curves were drawn to evaluate the usefulness of classic myocardial markers
including CK-MB, AST and LDH in diagnosing MI, as presented in Figure 1. As shown in
Table 3, only CK-MB had a significant diagnostic value in MI with AUC of 0.749 at the
optimal cut-off value of 3.035 (P=0.000). The sensitivity was 0.593, and the specificity was
0.905. AST and LDH had no diagnostic significance for MI in PH patients at high altitude.

9

10 4. Discussion

11 Millions of tourists and climbers visit high altitudes annually. Many healthy individuals 12 may suffer from altitude illnesses when visiting to these high regions, including acute 13 mountain sickness (AMS), high altitude cerebral edema and high altitude pulmonary edema 14 (HAPE) and, notably, PH, which can eventually lead to right ventricle hypertrophy and heart failure^[16]. Furthermore, increased pulmonary artery pressures, acute hypoxia, increased 15 16 myocardial work, and increased epinephrine release may cause or exacerbate MI at high altitude^[17]. At present, there are few studies focusing on MI with PH at high altitude. In the 17 18 present research, the prevalence of MI was 12.6%, which lower than our previous study^[7, 18]. 19 One possible reason for the lower prevalence was that different diagnostic standards were 20 used. To be specific, due to the limitation of high altitude environment, the previous studies 21 used CK, CK-MB, LDH, and AST to diagnose MI, while cTnI was used in present study. In 22 addition, altitude acclimatization may be another important contributor. This study mainly

| 1 | included population with long-term exposure to the high altitude and aborigines, so adaptive |
|----|--|
| 2 | changes may occur in the cardiovascular system, making the heart more tolerant to hypoxia. |
| 3 | Adaptation to high-altitude hypoxia increases the cardiac tolerance of highlanders to all the |
| 4 | major deleterious consequences of acute hypoxia. Hypoxia inducible factor (HIF) pathway, |
| 5 | mitochondrial synthesis pathway, blood oxygen transport pathway, tissue oxygen transport |
| 6 | pathway, energy metabolism pathway and other pathways play an important role in the |
| 7 | process of myocardial adaptation to high altitude ^[19] . Evidence suggested that modifications of |
| 8 | the HIF pathway is a crucial mechanism in altitude acclimatization. EGLN1 and EPAS1 is |
| 9 | encode major components of the HIF transcriptional pathway, which coordinates an |
| 10 | organism's response to hypoxia ^[20-22] . In a hypoxic environment at high altitude, the hearts |
| 11 | initiate transcriptional programs to increase dependence on carbohydrates over fatty acid for |
| 12 | ATP production, with altered mitochondrial structure and function that improve metabolic |
| 13 | efficiency and reduce ROS generation, as well as beneficial changes in glycogen storage and |
| 14 | high energy phosphate system to regulate the balance between energy demand and energy |
| 15 | supply when oxygen is limited ^[23] . In addition, Schweizer et al. ^[24] found that heart rate is |
| 16 | increased to improve the delivery of circulating oxygen at high altitude, and attenuation of |
| 17 | catecholamine release improves tissue blood flow during hypoxia. The changes of Hb |
| 18 | function, oxygen transport and aerobic capacity under high altitude play a vital role in the |
| 19 | process of hypoxic adaptation ^[25] , including the evolution of higher rates of alveolar |
| 20 | ventilation and respiratory oxygen uptake ^[26] , higher Hb O2 affinity ^[27] , as well as altered |
| 21 | skeletal muscle phenotypes enhance the ability of tissue O2 diffusion and O2 utilization ^[28, 29] . |
| 22 | It is well known that obesity has adverse effects on cardiovascular hemodynamics and |

1 cardiac structure and function, thus increasing the incidence of adverse cardiovascular events^[30]. Evidence suggests that obesity is a risk factors for AMS and is associated with its 2 development^[31]. In present study, MI group had a higher BMI than the non-MI group. Thus, 3 4 Elevated BMI may be a risk factor for MI expose to high altitude. Previous study 5 demonstrated that among individuals without cardiovascular disease, higher BMI was independently linearly associated with subclinical MI^[32]. Obesity leads to myocardial 6 dysfunction by endocrine and inflammatory effects of adipose tissue^[33]. However, what's 7 8 interesting is that obesity appeared to be associated with a lower risk of death once cardiovascular disease was present^[34]. This phenomenon has been called the "obesity para-9 10 dox"^[35].

11 In this retrospective research, we also found that LVEDD altered significantly in MI with 12 PH under high-altitude exposure. Left ventricular dilatation is usually the result of multiple 13 pathological changes that occur during myocardial remodeling in progressive heart failure. 14 There is an outward remodeling of the left ventricular myocardium during MI, which results in left ventricular dilatation^[36]. In our study, the presence of increased LVEDD in MI group 15 16 may indicate the heart was going into decompensation phase. Dilated LVEDD was related to left ventricular dysfunction and may be a signal of advanced heart disease^[37]. Left ventricular 17 18 dilatation is an independent predictor of MI^[38]. Chen et al. ^[39] suggested that LVEDD may be 19 used to identify heart fail patients who require more aggressive therapeutic interventions. Left 20 ventricular (LV) enlargement is an independent predictor of cardiovascular events in patients, 21 and the addition of LV volumes to LV diameters increased the predictive value for cardiovascular outcomes ^[40]. Therefore, screening for LVEDD dilatation in the general 22

1 population at high altitude may identify a high-risk population for preventive treatment.

| 2 | Although Troponin has been regarded as the gold-standard biomarker for MI ^[41] , other |
|----|---|
| 3 | myocardial enzymes may be helpful in cases where troponin cannot be detected. CK-MB is |
| 4 | relatively specific for myocardial tissue, and CK-MB levels are most valuable for the |
| 5 | diagnosis of myocardial infarction when skeletal muscle injury or disease is excluded, but the |
| 6 | expression of AST and LDH in a wide variety of tissues significantly affects its specificity for |
| 7 | MI ^[42] . In our study, it has been suggested that CK-MB and LDH were closely associated with |
| 8 | the expression of cTnI. Furthermore, ROC curve was drawn to demonstrate that CK-MB level |
| 9 | could predict the occurrence of MI with an AUC of 0.749 to a limited extent. Similarly, |
| 10 | Previous studies have suggested that CK-MB provides a reliable and specific diagnosis with |
| 11 | high accuracy in the first few hours of onset of cardiac symptoms ^[43] . However, AST and LDH |
| 12 | were dropped due to lack of specificity in the diagnosis of acute myocardial infarction ^[44] . |
| 13 | Thus, we suggest that CK-MB may be a good diagnostic marker when it is hard to measure of |
| 14 | cTnI in highlanders. |

15

16 5. Conclusion

In summary, incidence of MI with PH is high in population at high altitude. BMI, LVEDD and CK-MB altered significantly in MI with PH under high altitude exposure. As a convenient marker, CK-MB is found to be closely associated with cTnI and have an effective diagnostic value in the high-altitude MI with PH. The biggest limitation in our present study is that only patients with PH are included, so whether the findings can be extended to all population at high altitude still needs further study.

1

2 CRediT authorship contribution statement

| 3 | MZ: Data curation, Formal analysis, Writing-Original Draft; QW: Data curation, |
|----|---|
| 4 | Validation, Visualization; WD: Data curation, Writing-Original Draft; JS: Data curation, |
| 5 | Validation; WY: Data curation, Validation; YS: Data curation, Validation; XZ: Formal |
| 6 | analysis, Writing-Reviewing and Editing; JZ: Supervision, Writing-Reviewing and Editing; |
| 7 | SH: Conceptualization, Supervision, Funding acquisition, Writing-Reviewing and Editing. |
| 8 | |
| 9 | Fundings |
| 10 | This study is granted by Natural Science Foundation of Sichuan Province (No. |
| 11 | 2022NSFSC1295), the 2021 annal project of the General Hospital of Western Theater |
| 12 | Command (No. 2021-XZYG-B31). |
| 13 | |
| 14 | Conflict of interest |
| 15 | The authors declare that the research was conducted in the absence of any commercial or |
| 16 | financial relationships that could be construed as a potential conflict of interest. |
| 17 | |
| 18 | Publisher's note |
| 19 | All claims expressed in this article are solely those of the authors and do not necessarily |
| 20 | represent those of their affiliated organizations, or those of the publisher, the editors and the |
| 21 | reviewers. Any product that may be evaluated in this article, or claim that may be made by its |
| 22 | manufacturer, is not guaranteed or endorsed by the publisher. |

1

2 References

- TREMBLAY J C, AINSLIE P N. Global and country-level estimates of human
 population at high altitude [J]. Proceedings of the National Academy of Sciences of
- 5 the United States of America, 2021, 118(18).
- 6 [2] LUO G, JIAN Z, ZHU Y, et al. Sirt1 promotes autophagy and inhibits apoptosis to
 7 protect cardiomyocytes from hypoxic stress [J]. International journal of molecular
 8 medicine, 2019, 43(5): 2033-43.
- 9 [3] HOU J, WEN X, LONG P, et al. The role of post-translational modifications in
 10 driving abnormal cardiovascular complications at high altitude [J]. Frontiers in
 11 cardiovascular medicine, 2022, 9: 886300.
- 12 [4] ALDASHEV A A, SARYBAEV A S, SYDYKOV A S, et al. Characterization of high-
- altitude pulmonary hypertension in the Kyrgyz: association with angiotensinconverting enzyme genotype [J]. American journal of respiratory and critical care
 medicine, 2002, 166(10): 1396-402.
- 16 [5] FURIAN M, LATSHANG T D, AESCHBACHER S S, et al. Markers of
 17 cardiovascular risk and their reversibility with acute oxygen therapy in Kyrgyz
 18 highlanders with high altitude pulmonary hypertension [J]. Pulmonology, 2021,
 19 27(5): 394-402.
- LüSCHER T F. Refining cardiovascular risk: anthropometric measures, potassium,
 high altitude exposure, and cancer therapy [J]. European heart journal, 2018, 39(17):
 1499-502.

1 [7] HE S, HE S, YANG Y, et al. Correlation Between Neutrophil to Lymphocyte Ratio

- and Myocardial Injury in Population Exposed to High Altitude [J]. Frontiers in
 cardiovascular medicine, 2021, 8: 738817.
- [8] NEVES A L, HENRIQUES-COELHO T, LEITE-MOREIRA A, et al. Cardiac injury
 biomarkers in paediatric age: Are we there yet? [J]. Heart failure reviews, 2016,
 21(6): 771-81.
- 7 [9] MAIR J, LINDAHL B, HAMMARSTEN O, et al. How is cardiac troponin released
 8 from injured myocardium? [J]. European heart journal Acute cardiovascular care,
- 9 2018, 7(6): 553-60.
- 10 [10] PARK K C, GAZE D C, COLLINSON P O, et al. Cardiac troponins: from myocardial
- 11 infarction to chronic disease [J]. Cardiovascular research, 2017, 113(14): 1708-18.
- 12 [11] PARSANATHAN R, JAIN S K. Novel Invasive and Noninvasive Cardiac-Specific
- Biomarkers in Obesity and Cardiovascular Diseases [J]. Metabolic syndrome and
 related disorders, 2020, 18(1): 10-30.
- 15 [12] HE B, WANG J, QIAN G, et al. Analysis of high-altitude de-acclimatization
- 16 syndrome after exposure to high altitudes: a cluster-randomized controlled trial [J].
- 17 PloS one, 2013, 8(5): e62072.
- [13] ZHOU Q, YANG S, LUO Y, et al. A randomly-controlled study on the cardiac
 function at the early stage of return to the plains after short-term exposure to high
 altitude [J]. PloS one, 2012, 7(2): e31097.
- [14] HUMBERT M, KOVACS G, HOEPER M M, et al. 2022 ESC/ERS Guidelines for the
 diagnosis and treatment of pulmonary hypertension [J]. European heart journal, 2022,

| 43(38): 3618-731. |
|-------------------|
| |

| 2 | [15] | THYGESEN K, ALPERT J S, JAFFE A S, et al. Fourth Universal Definition of |
|----|------|--|
| 3 | | Myocardial Infarction (2018) [J]. Circulation, 2018, 138(20): e618-e51. |
| 4 | [16] | PENA E, EL ALAM S, SIQUES P, et al. Oxidative Stress and Diseases Associated |
| 5 | | with High-Altitude Exposure [J]. Antioxidants (Basel, Switzerland), 2022, 11(2). |
| 6 | [17] | HIGGINS J P, TUTTLE T, HIGGINS J A. Altitude and the heart: is going high safe |
| 7 | | for your cardiac patient? [J]. American heart journal, 2010, 159(1): 25-32. |
| 8 | [18] | HE S, ZHANG Q, WU F, et al. Influence of cigarettes on myocardial injury in healthy |
| 9 | | population after exposure to high altitude over 5000 m [J]. The Science of the total |
| 10 | | environment, 2023, 855: 158824. |
| 11 | [19] | OSTADAL B, KOLAR F. Cardiac adaptation to chronic high-altitude hypoxia: |
| 12 | | beneficial and adverse effects [J]. Respiratory physiology & neurobiology, 2007, |
| 13 | | 158(2-3): 224-36. |
| 14 | [20] | PETOUSI N, CROFT Q P, CAVALLERI G L, et al. Tibetans living at sea level have a |
| 15 | | hyporesponsive hypoxia-inducible factor system and blunted physiological responses |
| 16 | | to hypoxia [J]. Journal of applied physiology (Bethesda, Md : 1985), 2014, 116(7): |
| 17 | | 893-904. |
| 18 | [21] | XIANG K, OUZHULUOBU, PENG Y, et al. Identification of a Tibetan-specific |
| 19 | | mutation in the hypoxic gene EGLN1 and its contribution to high-altitude adaptation |
| 20 | | [J]. Molecular biology and evolution, 2013, 30(8): 1889-98. |
| 21 | [22] | XIN J, ZHANG H, HE Y, et al. Chromatin accessibility landscape and regulatory |
| 22 | | network of high-altitude hypoxia adaptation [J]. Nature communications, 2020, 11(1): |

| 1 | 4928. |
|---|-------|
| | |

2 [23] SU Z, LIU Y, ZHANG H. Adaptive Cardiac Metabolism Under Chronic Hypoxia: 3 Mechanism and Clinical Implications [J]. Frontiers in cell and developmental 4 biology, 2021, 9: 625524. 5 SCHWEIZER R M, VELOTTA J P, IVY C M, et al. Physiological and genomic [24] 6 evidence that selection on the transcription factor Epas1 has altered cardiovascular 7 function in high-altitude deer mice [J]. PLoS genetics, 2019, 15(11): e1008420. 8 [25] STORZ J F. High-Altitude Adaptation: Mechanistic Insights from Integrated 9 Genomics and Physiology [J]. Molecular biology and evolution, 2021, 38(7): 2677-91. 10 11 IVY C M, SCOTT G R. Control of breathing and ventilatory acclimatization to [26] 12 hypoxia in deer mice native to high altitudes [J]. Acta physiologica (Oxford, 13 England), 2017, 221(4): 266-82. 14 [27] STORZ J F, RUNCK A M, MORIYAMA H, et al. Genetic differences in hemoglobin 15 function between highland and lowland deer mice [J]. The Journal of experimental 16 biology, 2010, 213(Pt 15): 2565-74. 17 SCOTT G R, ELOGIO T S, LUI M A, et al. Adaptive Modifications of Muscle [28] 18 Phenotype in High-Altitude Deer Mice Are Associated with Evolved Changes in Gene Regulation [J]. Molecular biology and evolution, 2015, 32(8): 1962-76. 19 20 [29] MAHALINGAM S, MCCLELLAND G B, SCOTT G R. Evolved changes in the 21 intracellular distribution and physiology of muscle mitochondria in high-altitude native deer mice [J]. The Journal of physiology, 2017, 595(14): 4785-801. 22

1 [30] LAVIE C J, PANDEY A, LAU D H, et al. Obesity and Atrial Fibrillation Prevalence,

- 2 Pathogenesis, and Prognosis: Effects of Weight Loss and Exercise [J]. Journal of the
- 3 American College of Cardiology, 2017, 70(16): 2022-35.
- 4 [31] CARAVEDO M A, MOZO K, MORALES M L, et al. Risk factors for acute mountain
- sickness in travellers to Cusco, Peru: coca leaves, obesity and sex [J]. Journal of
 travel medicine, 2022, 29(5).
- 7 [32] NDUMELE C E, CORESH J, LAZO M, et al. Obesity, subclinical myocardial injury,
- 8 and incident heart failure [J]. JACC Heart failure, 2014, 2(6): 600-7.
- 9 [33] MARTIN S S, QASIM A, REILLY M P. Leptin resistance: a possible interface of
- inflammation and metabolism in obesity-related cardiovascular disease [J]. Journal of
 the American College of Cardiology, 2008, 52(15): 1201-10.
- 12 [34] BUETTNER H J, MUELLER C, GICK M, et al. The impact of obesity on mortality
- in UA/non-ST-segment elevation myocardial infarction [J]. European heart journal,
 2007. 28(14): 1604.701
- 14 2007, 28(14): 1694-701.
- 15 [35] HIDVEGI R, PUELACHER C, GUALANDRO D M, et al. Obesity paradox and
- perioperative myocardial infarction/injury in non-cardiac surgery [J]. Clinical
 research in cardiology : official journal of the German Cardiac Society, 2020, 109(9):
- **18** 1140-7.
- 19 [36] KONSTAM M A, KRAMER D G, PATEL A R, et al. Left ventricular remodeling in
 20 heart failure: current concepts in clinical significance and assessment [J]. JACC
 21 Cardiovascular imaging, 2011, 4(1): 98-108.
- 22 [37] ALEONG R G, MULVAHILL M J, HALDER I, et al. Left Ventricular Dilatation

| 1 | | Increases the Risk of Ventricular Arrhythmias in Patients With Reduced Systolic |
|----------------------------------|------|---|
| 2 | | Function [J]. Journal of the American Heart Association, 2015, 4(8): e001566. |
| 3 | [38] | YEBOAH J, BLUEMKE D A, HUNDLEY W G, et al. Left ventricular dilation and |
| 4 | | incident congestive heart failure in asymptomatic adults without cardiovascular |
| 5 | | disease: multi-ethnic study of atherosclerosis (MESA) [J]. Journal of cardiac failure, |
| 6 | | 2014, 20(12): 905-11. |
| 7 | [39] | CHEN Y C, HSING S C, CHAO Y P, et al. Clinical Relevance of the LVEDD and |
| 8 | | LVESD Trajectories in HF Patients With LVEF < 35 [J]. Frontiers in medicine, 2022, |
| 9 | | 9: 846361. |
| 10 | [40] | ITO K, LI S, HOMMA S, et al. Left ventricular dimensions and cardiovascular |
| 11 | | outcomes in systolic heart failure: the WARCEF trial [J]. ESC heart failure, 2021, |
| 12 | | 8(6): 4997-5009. |
| 13 | [41] | THYGESEN K, ALPERT J S, JAFFE A S, et al. Third universal definition of |
| 15 | [41] | THE OBSERVER, MELENER 5, 5, 574 FE TY 5, 50 al. Third universal definition of |
| 13 | [41] | myocardial infarction [J]. Circulation, 2012, 126(16): 2020-35. |
| | [41] | |
| 14 15 | | myocardial infarction [J]. Circulation, 2012, 126(16): 2020-35. |
| 14 | | myocardial infarction [J]. Circulation, 2012, 126(16): 2020-35. TILEA I, VARGA A, SERBAN R C. Past, Present, and Future of Blood Biomarkers |
| 14 15 16 | | myocardial infarction [J]. Circulation, 2012, 126(16): 2020-35. TILEA I, VARGA A, SERBAN R C. Past, Present, and Future of Blood Biomarkers for the Diagnosis of Acute Myocardial Infarction-Promises and Challenges [J]. |
| 14 15 16 17 | [42] | myocardial infarction [J]. Circulation, 2012, 126(16): 2020-35. TILEA I, VARGA A, SERBAN R C. Past, Present, and Future of Blood Biomarkers for the Diagnosis of Acute Myocardial Infarction-Promises and Challenges [J]. Diagnostics (Basel, Switzerland), 2021, 11(5). |
| 14 15 16 17 18 | [42] | myocardial infarction [J]. Circulation, 2012, 126(16): 2020-35. TILEA I, VARGA A, SERBAN R C. Past, Present, and Future of Blood Biomarkers for the Diagnosis of Acute Myocardial Infarction-Promises and Challenges [J]. Diagnostics (Basel, Switzerland), 2021, 11(5). DANESE E, MONTAGNANA M. An historical approach to the diagnostic |
| 14 15 16 17 18 19 | [42] | myocardial infarction [J]. Circulation, 2012, 126(16): 2020-35. TILEA I, VARGA A, SERBAN R C. Past, Present, and Future of Blood Biomarkers for the Diagnosis of Acute Myocardial Infarction-Promises and Challenges [J]. Diagnostics (Basel, Switzerland), 2021, 11(5). DANESE E, MONTAGNANA M. An historical approach to the diagnostic biomarkers of acute coronary syndrome [J]. Annals of translational medicine, 2016, |

1 Figure Legend

- 2 Figure 1. Receiver operating characteristic (ROC) curve for the values of (A) creatine kinase-
- 3 MB (CK-MB), (B) aspartate aminotransferase (AST) and (C) lactic dehydrogenase (LDH) in
- 4 diagnosing myocardial injury with pulmonary hypertension.

| Variables | MI group | non-MI group | P Value | |
|--------------------------------------|--------------------|-----------------|---------|--|
| | (n=29) | (n=202) | i value | |
| Age (y) | 55.1±18.0 | 48.9±19.7 | 0.117 | |
| Male | 23 | 134 | 0.205 | |
| BMI (kg/m ²) | 26.1±4.0 | 24.4±4.2 | 0.045* | |
| Living altitude (km) | 3650(3600-4400) | 3650(3600-3800) | 0.422 | |
| Aborigines | 20 | 121 | 0.415 | |
| Smoke | 13 | 66 | 0.454 | |
| TVR velocity (cm/s) | 339(288-382.5) | 320(290-390.25) | 0.713 | |
| LVEDD (mm) | 44(41.5-52.5) | 42(40-45) | 0.005** | |
| HR (/min) | 74(67.5-86) | 79(68-92.25) | 0.270 | |
| RBC (*10 ² /L) | 6.0±1.2 | 5.8±1.2 | 0.407 | |
| Hemoglobin (g/L) | 168.3±35.5 | 168.3±35.5 | 0.686 | |
| Platelet count (*10 ⁹ /L) | 192.0±80.0 | 185.9±75.4 | 0.692 | |
| RDW | 48(44-57) | 48(44-57) | 0.606 | |
| PDW | 13(11-14.75) | 13(11-15) | 0.920 | |
| ALT (U/L) | 22(12.5-35) | 23.5(16-37) | 0.247 | |
| AST (U/L) | 20(16.5-31.5) | 23(17-33) | 0.465 | |
| Total bilirubin (µmol/L) | 19.5(11.6-28.9) | 17.5(12.6-28.6) | 0.720 | |
| Direct bilirubin (µmol/L) | 5.7(3.6-12.8) | 5.6(3.4-10.1) | 0.450 | |
| Albumin (g/L) | 39.9(34.7-45.0) | 41.5(35.7-45.7) | 0.534 | |
| Globulin (g/L) | 31.3(26.6-34.3) | 29(25.6-33) | 0.106 | |
| Urea nitrogen (mmol/L) | 5.6(4.3-6.2) | 5.4(4.1-6.6) | 0.791 | |
| Creatinine (µmol/L) | 76.2(63.5-87.7) | 72(57.4-81.7) | 0.268 | |
| Uric acid (umol/L) | 462.0±138.3 | 454.6±144.8 | 0.797 | |
| Total cholesterol (mmol/L) | 4.3±1.1 | 4.0±1.2 | 0.216 | |
| Triglyceride (mmol/L) | 1.2(0.9-1.8) | 1.1(0.8-1.6) | 0.291 | |
| HDL-C (mmol/L) | $1.1{\pm}0.4$ | 1.0±0.3 | 0.507 | |
| LDL-C (mmol/L) | 2.4±1.0 | 2.2±0.9 | 0.280 | |
| ApoA1 (g/L) | 1.16(0.93-1.26) | 1.13(1.02-1.23) | 0.940 | |
| ApoB (g/L) | 0.8±0.2 | $0.7{\pm}0.2$ | 0.180 | |
| LDH (U/L) | 239.5(162.3-293.8) | 198(156.6-276) | 0.264 | |

¹ **Table 1.** Comparisons of clinical data between MI group and non-MI group.

| CK-MB (ng/mL) | 3.47(2.1-7.6) | 1.37(1.1-2.4) | 0.001** |
|---------------|-----------------|-----------------|---------|
| PT (s) | 11.1(10.4-14.3) | 11.4(10.6-12.6) | 0.937 |
| APTT (s) | 34.3(29.9-47.1) | 33.8(30.3-39.2) | 0.328 |
| D-D | 0.2(0.2-2.3) | 0.3(0.2-0.9) | 0.926 |

1 MI-myocardial injury; BMI-body mass index; TVR-tricuspid valve regurgitation; LVEDD-2 left ventricular end-diastolic dimension; HR=heart rate; RBC=red blood cell count; RDW=red 3 blood cell distribution width; PDW=platelet distribution width; ALT=alanine transaminase; 4 AST=aspartate aminotransferase; HDL-C= high density lipoprotein cholesterin; LDL-C= low 5 density lipoprotein cholesterin; ApoA1=apolipoprotein A1; ApoB=apolipoprotein B; LDH=lactate dehydrogenase; CK-MB=creatine kinase-MB; PT=prothrombin time; 6 7 APTT=activated partial thromboplastin time; D-D=D-dimer. 8 * Indicates significance at level 0.05 9 ** Indicates significance at level 0.01 10 Bold value indicates difference is significant.

1 **Table 2.** Correlation between cTnI and other myocardial enzymes.

2

| | СК-МВ | AST | LDH |
|-----------------|-------|-------|-------|
| coefficient (r) | 0.571 | 0.009 | 0.212 |
| P value | 0.000 | 0.891 | 0.001 |

3

4 CK-MB=creatine kinase-MB; AST=aspartate aminotransferase; LDH=lactate dehydrogenase.

5 Bold value indicates difference is significant.

6

| | СК-МВ | AST | LDH |
|---------------|-------|--------|---------|
| AUC | 0.749 | 0.542 | 0.565 |
| Youden index | 0.498 | 0.141 | 0.206 |
| Cut-off value | 3.035 | 22.500 | 233.500 |
| Sensitivity | 0.593 | 0.379 | 0.571 |
| Specificity | 0.905 | 0.480 | 0.635 |
| P value | 0.000 | 0.466 | 0.264 |

1 **Table 3.** Diagnostic value of CK-MB, AST and LDH for MI.

3

2

4 CK-MB=creatine kinase-MB; AST=aspartate aminotransferase; LDH=lactate dehydrogenase;

5 MI=myocardial injury; AUC=area under curve.

6 Bold value indicates difference is significant.

7

| | CK-MB | AST | LDH |
|-----------------|-------|-------|-------|
| coefficient (r) | 0.571 | 0.009 | 0.212 |
| P value | 0.000 | 0.891 | 0.001 |

Table 2. Correlation between cTnI and other myocardial enzymes.

CK-MB=creatine kinase-MB; AST=aspartate aminotransferase; LDH=lactate dehydrogenase.

Bold value indicates difference is significant.

| | CK-MB | AST | LDH |
|---------------|-------|--------|---------|
| AUC | 0.749 | 0.542 | 0.565 |
| Youden index | 0.498 | 0.141 | 0.206 |
| Cut-off value | 3.035 | 22.500 | 233.500 |
| Sensitivity | 0.593 | 0.379 | 0.571 |
| Specificity | 0.905 | 0.480 | 0.635 |
| P value | 0.000 | 0.466 | 0.264 |

Table 3. Diagnostic value of CK-MB, AST and LDH for MI.

CK-MB=creatine kinase-MB; AST=aspartate aminotransferase; LDH=lactate dehydrogenase;

MI=myocardial injury; AUC=area under curve.

Bold value indicates difference is significant.

| V | MI group | non-MI group | P Value | |
|--------------------------------------|-----------------|-----------------|---------|--|
| Variables | (n=29) | (n=202) | | |
| Age (y) | 55.1±18.0 | 48.9±19.7 | 0.117 | |
| Male | 23 | 134 | 0.205 | |
| BMI (kg/m ²) | 26.1±4.0 | 24.4±4.2 | 0.045* | |
| Living altitude (km) | 3650(3600-4400) | 3650(3600-3800) | 0.422 | |
| Aborigines | 20 | 121 | 0.415 | |
| Smoke | 13 | 66 | 0.454 | |
| TVR velocity (cm/s) | 339(288-382.5) | 320(290-390.25) | 0.713 | |
| LVEDD (mm) | 44(41.5-52.5) | 42(40-45) | 0.005** | |
| HR (/min) | 74(67.5-86) | 79(68-92.25) | 0.270 | |
| RBC (*10 ² /L) | 6.0±1.2 | 5.8±1.2 | 0.407 | |
| Hemoglobin (g/L) | 168.3±35.5 | 168.3±35.5 | 0.686 | |
| Platelet count (*10 ⁹ /L) | 192.0±80.0 | 185.9±75.4 | 0.692 | |
| RDW | 48(44-57) | 48(44-57) | 0.606 | |
| PDW | 13(11-14.75) | 13(11-15) | 0.920 | |
| ALT (U/L) | 22(12.5-35) | 23.5(16-37) | 0.247 | |
| AST (U/L) | 20(16.5-31.5) | 23(17-33) | 0.465 | |
| Total bilirubin (µmol/L) | 19.5(11.6-28.9) | 17.5(12.6-28.6) | 0.720 | |
| Direct bilirubin (µmol/L) | 5.7(3.6-12.8) | 5.6(3.4-10.1) | 0.450 | |
| Albumin (g/L) | 39.9(34.7-45.0) | 41.5(35.7-45.7) | 0.534 | |
| Globulin (g/L) | 31.3(26.6-34.3) | 29(25.6-33) | 0.106 | |
| Urea nitrogen (mmol/L) | 5.6(4.3-6.2) | 5.4(4.1-6.6) | 0.791 | |
| Creatinine (µmol/L) | 76.2(63.5-87.7) | 72(57.4-81.7) | 0.268 | |
| Uric acid (umol/L) | 462.0±138.3 | 454.6±144.8 | 0.797 | |
| Total cholesterol (mmol/L) | 4.3±1.1 | 4.0±1.2 | 0.216 | |
| Triglyceride (mmol/L) | 1.2(0.9-1.8) | 1.1(0.8-1.6) | 0.291 | |

 Table 1. Comparisons of clinical data between MI group and non-MI group.

| HDL-C (mmol/L) | 1.1±0.4 | 1.0±0.3 | 0.507 |
|----------------|--------------------|-----------------|---------|
| LDL-C (mmol/L) | 2.4±1.0 | 2.2±0.9 | 0.280 |
| ApoA1 (g/L) | 1.16(0.93-1.26) | 1.13(1.02-1.23) | 0.940 |
| ApoB (g/L) | 0.8±0.2 | $0.7{\pm}0.2$ | 0.180 |
| LDH (U/L) | 239.5(162.3-293.8) | 198(156.6-276) | 0.264 |
| CK-MB (ng/mL) | 3.47(2.1-7.6) | 1.37(1.1-2.4) | 0.001** |
| PT (s) | 11.1(10.4-14.3) | 11.4(10.6-12.6) | 0.937 |
| APTT (s) | 34.3(29.9-47.1) | 33.8(30.3-39.2) | 0.328 |
| D-D | 0.2(0.2-2.3) | 0.3(0.2-0.9) | 0.926 |

MI=myocardial injury; BMI=body mass index; TVR=tricuspid valve regurgitation; LVEDD= left ventricular end-diastolic dimension; HR=heart rate; RBC=red blood cell count; RDW=red blood cell distribution width; PDW=platelet distribution width; ALT=alanine transaminase; AST=aspartate aminotransferase; HDL-C= high density lipoprotein cholesterin; LDL-C= low density lipoprotein cholesterin; ApoA1=apolipoprotein A1; ApoB=apolipoprotein B; LDH=lactate dehydrogenase; CK-MB=creatine kinase-MB; PT=prothrombin time; APTT=activated partial thromboplastin time; D-D=D-dimer.

* Indicates significance at level 0.05

** Indicates significance at level 0.01

Bold value indicates difference is significant.

